DPY19L1

Across TCGA pan-cancer cohorts, DPY19L1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DPY19L1 data layer compared with 27 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher DPY19L1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated DPY19L1 expression acts as an unfavorable survival marker, although some lineages such as COAD show a favorable association.

CCRCC, LSCC, and LUAD are the cancer types where DPY19L1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	II,III,IV	0.228	0.979	.003	43	view →
LSCC	DFS	Quartile	III,IV	0.247	0.890	.007	14	view →
LUAD	DFS	Quartile	All	0.489	1.000	.002	9	view →
COAD	DFS	Median	IV	1.000	0.605	.043	6	view →
HNSC	DFS	Median	IV	0.328	0.889	.014	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DPY19L1–CCRCC (OS)

Open the CCRCC breakdown →